KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of KalVista Pharmaceuticals (NASDAQ:KALV) from a sell rating to a hold rating in a research report report published on Saturday.

KALV has been the topic of several other research reports. Citigroup restated a “market outperform” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. Citizens Jmp dropped their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a report on Tuesday, November 11th. Cowen reiterated a “buy” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Thursday, December 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, KalVista Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $26.63.

KalVista Pharmaceuticals Price Performance

KalVista Pharmaceuticals stock opened at $16.86 on Friday. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $17.28. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. The firm’s fifty day moving average is $12.39 and its 200 day moving average is $13.06. The company has a market cap of $852.27 million, a price-to-earnings ratio of -4.27 and a beta of -0.14.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.04. The business had revenue of $13.69 million during the quarter, compared to the consensus estimate of $6.03 million. Sell-side analysts forecast that KalVista Pharmaceuticals will post -3.56 EPS for the current fiscal year.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, insider Paul K. Audhya sold 5,296 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $13.45, for a total value of $71,231.20. Following the completion of the sale, the insider owned 131,831 shares in the company, valued at approximately $1,773,126.95. The trade was a 3.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Brian Piekos sold 4,471 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $13.45, for a total transaction of $60,134.95. Following the completion of the sale, the chief financial officer directly owned 10,529 shares of the company’s stock, valued at $141,615.05. The trade was a 29.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 24,035 shares of company stock valued at $316,948. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Sherbrooke Park Advisers LLC bought a new position in KalVista Pharmaceuticals in the third quarter worth about $191,000. Qube Research & Technologies Ltd lifted its position in KalVista Pharmaceuticals by 234.6% during the third quarter. Qube Research & Technologies Ltd now owns 325,435 shares of the specialty pharmaceutical company’s stock valued at $3,964,000 after acquiring an additional 228,187 shares during the last quarter. Parkman Healthcare Partners LLC boosted its stake in KalVista Pharmaceuticals by 155.5% in the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after acquiring an additional 1,055,940 shares in the last quarter. Brevan Howard Capital Management LP grew its holdings in KalVista Pharmaceuticals by 319.1% in the third quarter. Brevan Howard Capital Management LP now owns 55,878 shares of the specialty pharmaceutical company’s stock worth $681,000 after purchasing an additional 42,545 shares during the last quarter. Finally, Creative Planning increased its position in shares of KalVista Pharmaceuticals by 13.9% during the third quarter. Creative Planning now owns 38,032 shares of the specialty pharmaceutical company’s stock worth $463,000 after purchasing an additional 4,652 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).